Drug Combination Details
| General Information of the Combination (ID: C30154) | |||||
|---|---|---|---|---|---|
| Name | Celastrol NP Info | + | Temozolomide Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Melanoma
[ICD-11: 2C30]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Phosphorylation | ERK1 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Phosphorylation | JNK1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Phosphorylation | NFKBIA | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | p105 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | SK-MEL-19 | CVCL_6025 | Cutaneous melanoma | Homo sapiens | ||
| SK-MEL-100 | CVCL_6067 | Cutaneous melanoma | Homo sapiens | |||
| SK-MEL-173 | CVCL_6090 | Melanoma | Homo sapiens | |||
| SK-MEL-192 | CVCL_6101 | Melanoma | Homo sapiens | |||
| Experimental
Result(s) |
Celastrol synergistically enhances temozolomide cytotoxicity in melanoma cells. Celastrol treatment increased the levels of ubiquitinated proteins, reduced the levels of tumor necrosis factor-alpha-induced IkappaB phosphorylation, and blocked NF-kappaB translocation to the nucleus. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Celastrol synergistically enhances temozolomide cytotoxicity in melanoma cells. Mol Cancer Res. 2009 Dec;7(12):1946-53. | |||
